Sanofi SA (SAN) - Total Assets
Based on the latest financial reports, Sanofi SA (SAN) holds total assets worth €126.81 Billion EUR as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sanofi SA - Total Assets Trend (1999–2025)
This chart illustrates how Sanofi SA's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sanofi SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Sanofi SA's total assets of €126.81 Billion consist of 24.4% current assets and 75.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.78 Billion | 6.0% |
| Accounts Receivable | €397.00 Million | 0.3% |
| Inventory | €10.21 Billion | 8.1% |
| Property, Plant & Equipment | €11.51 Billion | 9.1% |
| Intangible Assets | €26.26 Billion | 20.7% |
| Goodwill | €67.56 Billion | 53.3% |
Asset Composition Trend (1999–2025)
This chart illustrates how Sanofi SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi SA's current assets represent 24.4% of total assets in 2025, a decrease from 68.0% in 1999.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, up from 3.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 73.0% of total assets, an increase from 3.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 53.3% of total assets.
Sanofi SA Competitors by Total Assets
Key competitors of Sanofi SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ono Pharmaceutical Co. Ltd
MU:ON4
|
Germany | €1.06 Trillion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Sanofi SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.46 | 1.75 |
| Quick Ratio | 0.73 | 1.14 | 0.79 |
| Cash Ratio | 0.27 | 0.26 | 0.00 |
| Working Capital | €2.61 Billion | €13.43 Billion | €14.51 Billion |
Sanofi SA - Advanced Valuation Insights
This section examines the relationship between Sanofi SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -4.5% |
| Total Assets | €126.81 Billion |
| Market Capitalization | $95.70 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sanofi SA's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sanofi SA's assets decreased by 4.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sanofi SA (1999–2025)
The table below shows the annual total assets of Sanofi SA from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €126.81 Billion | -4.51% |
| 2024-12-31 | €132.80 Billion | +5.01% |
| 2023-12-31 | €126.46 Billion | +1.51% |
| 2022-12-31 | €124.58 Billion | +3.61% |
| 2021-12-31 | €120.24 Billion | +4.99% |
| 2020-12-31 | €114.53 Billion | +1.59% |
| 2019-12-31 | €112.74 Billion | +1.19% |
| 2018-12-31 | €111.41 Billion | +11.62% |
| 2017-12-31 | €99.81 Billion | -4.64% |
| 2016-12-31 | €104.67 Billion | +2.30% |
| 2015-12-31 | €102.32 Billion | +5.06% |
| 2014-12-31 | €97.39 Billion | +1.39% |
| 2013-12-31 | €96.06 Billion | -4.34% |
| 2012-12-31 | €100.41 Billion | -0.26% |
| 2011-12-31 | €100.67 Billion | +18.07% |
| 2010-12-31 | €85.26 Billion | +6.51% |
| 2009-12-31 | €80.05 Billion | +11.20% |
| 2008-12-31 | €71.99 Billion | +4.33% |
| 2007-12-31 | €69.00 Billion | -7.09% |
| 2006-12-31 | €74.27 Billion | -14.58% |
| 2005-12-31 | €86.94 Billion | +1.80% |
| 2004-12-31 | €85.41 Billion | +777.62% |
| 2003-12-31 | €9.73 Billion | +2.79% |
| 2002-12-31 | €9.47 Billion | -5.01% |
| 2001-12-31 | €9.97 Billion | +27.05% |
| 2000-12-31 | €7.84 Billion | +14.96% |
| 1999-12-31 | €6.82 Billion | -- |
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more